Innovator股票定義保護主動型ETF-6個月(4月/10月) APOC 深 滬
已收盤 11-06 16:00:00 美东时间
26.5533
-0.027
-0.10%
華盛通- 最 高26.5933
- 今 開26.56
- 成交量 8337股
- 最 低 26.5424
- 昨 收 26.58
- 總市值 8497.07万
- 52周最高 26.89
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 25.53
- 委 比 -60.00%
- 總股本 320.00万
- 歷史最高 26.89
- 量 比 0.30
- 振 幅 0.19%
- 歷史最低 24.60
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Cellectis presented preclinical data for its .HEAL-101, an in vivo base editor targeting APOC3 for severe hypertriglyceridemia. The data showed 70% human APOC3 editing and 76% triglyceride reduction after a single dose in murine models. The therapy demonstrated efficient, specific editing with liver-restricted activity. Cellectis plans to initiate a Phase 1 trial in China, with initial clinical data expected in late 2027.
10-27 07:15
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies
Arrowhead Pharmaceuticals (ARWR) on Sunday said its drug plozasiran sharply reduced triglyceride levels and acute pancreatitis events in two Phase 3 studies involving patients with severe hypertriglyc...
08-31 00:30
Spire Global Selected By Amadeus IT Group To Provide Automatic Dependent Surveillance–Broadcast Data Fusion For Integration Into Amadeus Virtual Airport Operations Center
Spire's multi-source ground and space-based data fusion to power real-time aircraft visibility within Amadeus' Virtual Airport Operations Center (vAPOC)Spire Global, Inc. (NYSE:SPIR) ("Spire" or "the Company"), a global
05-19 18:48
2026开年中国创新药BD交易刷新阶段新高 瑞博生物大涨超6%
①小核酸药物技术为何近期频繁获得国际制药巨头的高额授权合作？ ②在2026年开年创新药BD交易规模已达332.8亿美元的背景下，合作热潮是否可持续？
02-12 10:13
